Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease
Translational Medicine of Aging · 2020 · 4 · 117-120
DOI: 10.1016/j.tma.2020.07.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Medicine of Aging, 2020. Verfasst von Danielle E Mor und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology & LSI Genomics, Princeton University, Princeton, NJ, 08544, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, Princeton University.
Abstract (Originalsprache)
Mitochondrial dysfunction is thought to contribute to neurodegeneration in Parkinson's disease (PD), yet the cellular events that lead to mitochondrial disruption remain unclear. Post-mortem studies of PD patient brains and the use of complex I inhibitors to model the disease previously suggested a reduction in mitochondrial activity as a causative factor in PD, but this may represent an endpoint in the disease process. In our recent studies, we identified a novel link between branched-chain amino acid metabolism and PD, and uncovered mitochondrial hyperactivity as a potential alternative mechanism of PD pathogenesis. Increased mitochondrial activity may occur in a subset of PD patients, or may be a more common early event that precedes the ultimate loss of mitochondrial function. Therefore, it may be that any imbalance in mitochondrial activity, either increased or decreased, could cause a loss of mitochondrial homeostasis that leads to disease. An effective therapeutic strategy may be to target specific imbalances in activity at selective stages of PD or in specific patients, with any efforts to reduce mitochondrial activity constituting a surprising new avenue for PD treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology & LSI Genomics, Princeton University, Princeton, NJ, 08544, USA.
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- Princeton University
Zitieren
APA
Mor, D. E., & Murphy, C. T. (2020). Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease. Translational Medicine of Aging, 4, 117-120. https://doi.org/10.1016/j.tma.2020.07.007
Vancouver
Mor DE, Murphy CT. Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease. Translational Medicine of Aging. 2020;4:117-120. doi:10.1016/j.tma.2020.07.007
BibTeX
@article{Mor2020,
author = {Mor, Danielle E and Murphy, Coleen T},
title = {Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease},
journal = {Translational Medicine of Aging},
year = {2020},
volume = {4},
pages = {117--120},
doi = {10.1016/j.tma.2020.07.007}
}
EUVIMED